News
Geneva, Switzerland, August 31, 2021 - AMAL Therapeutics announced today that the latest findings of its in vivo research team, in collaboration with Prof. Guido Wollman’s lab at the Medical University of Innsbruck, is online on the Nature Communication website. The results show that combinatorial treatment with a protein-based cancer vaccine and an oncolytic virus elicits a potent immune response resulting in long lasting anti-tumoral efficacy in different tumor models, highlighting the potential for cancer treatment.
Geneva, Switzerland, July 1, 2021 – AMAL Therapeutics announced today that the latest findings of its in vivo research team is on line on the Frontiers in Immunology website.
Geneva, Switzerland, February 17, 2021 – AMAL Therapeutics announced today that its recent research findings, in collaboration with Fox Chase Cancer Center, about a novel protein‐based vaccine against self‐antigen reducing the formation of sporadic colon adenomas in mice, is on line on the Cancers website.
A very happy holiday season from the whole AMAL team, and a great start into 2021!
We are very happy to welcome Thomas Bogenrieder, MD, PhD, as Chief Clinical Officer of AMAL Therapeutics as of July 1, 2020. Thomas will join AMAL’s operations in Geneva.